Recovering from Incretin Mimetics Lawsuits
Type 2 Diabetes Drug Therapy
If drug therapy becomes necessary, drugs for type 2 diabetes reduce spikes of glucose in your bloodstream, increase the production of insulin, or open your cells to insulin. Excess glucose in your bloodstream damages blood vessels and nerves, which can lead to heart disease and stroke, kidney disease, and damage to your eyes. Metformin and sulfonylureas are frequently prescribed separately or in combination. Metformin may cause lactic acidosis in alcoholics, and sulfonylureas may accelerate liver and kidney disease in alcoholics.
Incretin Mimetics as a Treatment
Novo Nordisk's Victoza, approved by the U.S. Food and Drug Administration (FDA) in 2010, is an incretin mimetic. Incretin mimetic lowers blood sugar even in individuals with type 1 diabetes. The result of obesity and too much sugar in your diet can be that your pancreas stops producing insulin. Liraglutide, generic Victoza, acts as a synthetic glucagon peptide-1 (GLP-1) protein to the cause production of insulin.
Benefits of Incretin Mimetics
The usually conservative Mayo Clinic embraced the incretin mimetics finding them capable of modulating the immune system, replacing insulin, and acting as incretins, your pancreatic hormones. The incretin mimetics control the functions of the pancreas and improve weight loss. Colloquially, incretin mimetics mimic your abdominal hormone incretin and cause insulin to be released when your blood sugar is high. Incretin mimetics type 1 or type 2 diabetes drugs control blood sugar naturally and restore your body's vital functions.
Most patients well tolerate incretin mimetics. Some patients experience mild nausea which improves with continued use. Occasionally patients experience vomiting, loss of appetite, constipation, and lightheadedness. Novo Nordisk, Merck, Eli Lilly, and AstraZeneca subsidiary Amylin Pharmaceuticals, LLC, manufacture:
- Byetta, Bydureon (exenatide)
- Victoza (liraglutide)
- Tanzeum (albiglutide)
Diabetes Medications Lawsuit Timeline
The diabetes medications lawsuit differs from most class action defective product litigation in that the cases have been consolidated into multidistrict litigation across manufacturers and medications. The suits were consolidated because the incretin mimetic medications are mostly the same with the same serious complications.
The multidistrict litigation consolidated 700 federal cases against Novo Nordisk for Victoza, Merck for Januvia and Janumet, and Eli Lilly for Tradjenta alleging that the manufacturers failed to warn doctors and patients of the severe health risks of their products. Product liability consolidation is atypical. Manufacturers are almost always sued separately.
Novo Nordisk successfully defended Victoza stating that the FDA did not let them list pancreatic cancer as a possible side effect of their incretin mimetic product because there was not enough evidence that this was the case. Judge Anthony J. Battaglia dismissed the consolidated cases in the United States District Court for the Southern District of California.
Merck faced 1,260 product liability claims in June 2018 for Januvia and Janumet. Like Victoza, the Januvia claims were consolidated into a federal Januvia lawsuit. The allegations were dismissed by the U.S. District Court for the Southern District of California.
The U.S. Ninth Circuit Court of Appeals reversed the trial court’s ruling regarding all manufacturers' incretin mimetic drugs including Victoza and Januvia. The Ninth Circuit did not address issues raised in the appellate or appellee's briefs, but they decided that the district court made errors during discovery. The Ninth Circuit appellate court reversed and remanded the summary judgment for the manufacturers to the U.S. District Court for the Southern District of California for further investigation or discovery. Briefs for manufacturers and complainants were filed as of December 11, 2018, but stays of the court protect all claims against the manufacturers.